Table III.
Case series reporting bacterial and fungal infections in adult patients treated with GTX in the G-CSF era.
| Study | N (fungal /total) |
Underlying Condition |
Average GTX Dose |
Intervention | Outcome (Fungal) | Outcome (Bacterial) | Adverse Events |
|---|---|---|---|---|---|---|---|
| Grigg et al (1996) | 9/11 | BMT, HM, AA |
5·9 × 1010 | Therapeutic (8) Prophylactic (3) |
0% resolved, 67% successful prophylaxis (recent infection) |
100% resolved | No pulmonary reactions |
| Lee et al (2001) | 11/25 | HM | 6.6 × 1010 | Therapeutic | 73% favourable response | 45% favourable response | Pulmonary oedema (8%), hypoxia (4%), SVT (4%) |
| Illerhaus et al (2002) | 10/18 | HM | 2.6 × 1010 3.2 × 1010 |
Therapeutic (18), Prophylactic (16) |
55% IPA responded, no benefit of prophylactic GTX |
78% septicaemia responded |
CMV transmission, alloimmunization |
| Hübel et al (2002) | 57/74 | HM | 4·6–8·1 × 1010 | Therapeutic (paired controls) |
Non-progression in 18% mould, 55% yeast, no difference vs controls |
Fewer progressive bacterial infections in control group (p = 0.04) |
Fever (17.5%), chills (30%), desaturation and pulmonary oedema (1%) |
| Rutella et al (2003) | 7/20 | HM | 1.7 × 1010 | Therapeutic | 57% response, 100% fungaemia, 0% IFI |
54% response rate | Fever, chills, bronchospasm |
| Mousset et al (2005) | 31/44, 20/23 |
HSCT, HM | 4.3 × 1010 | Therapeutic (44), Prophylactic (23) |
78% response at 30 days, 58% survival at 100 days |
92% response at 30 days, 77% survival at 100 days |
NS |
| Safdar et al (2006) | 19/20 | HSCT, HM, | 5.6 × 1010 | Therapeutic | 45% CR or PR, 15% stable | NS | Transient dyspnoea (5%) |
| Ofran et al (2007) | 28/47 | HM, AA | 3.6 × 1010 | Therapeutic | 64% infection-related survival | 53% infection-related survival |
Pulmonary reactions (13%) |
| Quillen et al (2009a) | 18/32 | SAA | 6.8 × 1010 | Therapeutic | 44% survival, 33% CR, 22% PR, 17% stable, 28% progress |
58% overall survival to discharge |
HLA alloimmunization (17%), pulmonary (15%) |
| Al-Tanbal et al (2010) | 16/22 | SAA, HM, CGD |
2.8 × 1010/L | Therapeutic | 75% survival | 68% clinical improvement | TRALI (4.5%) |
| Ang & Linn (2011) | 13/15 | HM | 5.0 × 1010 | Therapeutic | 31% cleared | 63% cleared | NS |
| Kim et al (2011) | 37/128 | HM, AA | 0.96 × 109/kg | Therapeutic | 47% control of proven or probable IFI |
Overall control of infection 53% |
Fever (19%), hypotension (6.5%), respiratory (9%) |
| Safdar et al (2014) | 33/74 | HSCT, HM, other |
5.6 × 1010 | Therapeutic | 45% patients had IFI | 46% overall response | Fever (3%), respiratory (8%) |
| Wang et al (2014) | 31/56 | SAA | 0.92 × 1010 | Therapeutic | 87% 30-day, 58% 90-day, 52% 180-day survival |
92% 30-day, 84% 90-day, 84% 180-day survival |
Fever, chills, allergy, dyspnoea |
AA, aplastic anaemia; BMT, bone marrow transplantation; CGD, chronic granulomatous disease; CMV, cytomegalovirus; G-CSF, granulocyte colony-stimulating factor; GTX, granulocyte transfusion; HM, haematological malignancy; HSCT, haematopoietic stem cell transplant; IFI, invasive fungal infection; IPA, invasive pulmonary aspergillosis; NS, not specified; PR, partial response; SAA, severe aplastic anaemia; TRALI, transfusion associated acute lung injury.